Last reviewed · How we verify
DHA-PIP
At a glance
| Generic name | DHA-PIP |
|---|---|
| Also known as | DHA-piperaquine, Dihydroartemisinin-piperaquine |
| Sponsor | Armed Forces Research Institute of Medical Sciences, Thailand |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya
- Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults (PHASE2)
- Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy (PHASE2)
- Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults (PHASE2)
- Malaria Elimination Pilot Study in Military Forces in Cambodia (PHASE4)
- Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia: (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DHA-PIP CI brief — competitive landscape report
- DHA-PIP updates RSS · CI watch RSS
- Armed Forces Research Institute of Medical Sciences, Thailand portfolio CI